IN2013MN01218A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MN01218A IN2013MN01218A IN1218MUN2013A IN2013MN01218A IN 2013MN01218 A IN2013MN01218 A IN 2013MN01218A IN 1218MUN2013 A IN1218MUN2013 A IN 1218MUN2013A IN 2013MN01218 A IN2013MN01218 A IN 2013MN01218A
- Authority
- IN
- India
- Prior art keywords
- charge
- drugs
- designing
- biopolymers
- synthesizing
- Prior art date
Links
- 229920001222 biopolymer Polymers 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 230000003449 preventive effect Effects 0.000 abstract 3
- 230000002194 synthesizing effect Effects 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 101710163270 Nuclease Proteins 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002547 new drug Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 230000029936 alkylation Effects 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- -1 halogen carboxylic acids Chemical class 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Computing Systems (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention can be used in medicine and veterinary science for designing (creating and synthesizing) therapeutic and preventive drugs which are effective in the treatment of cancerous and viral diseases in humans and animals as well as for designing new drugs. The novel method for designing and synthesizing therapeutic and preventive drugs is characterized in that a target biopolymer (protein DNA RNA or a combination thereof) is identified and subsequently used as a ligand having been cleaved into oligomer fragments (by nucleases synthetic nucleases and proteases) which are modified by replacing the charge thereof with an opposite charge (by acylation with dicarboxylic acid anhydrides or alkylation with halogen carboxylic acids); the same target biopolymer is also used as a ligand having been modified by the partial replacement of the charge of the molecule with an opposite charge to form a supramolecular ensemble of biopolymers. A supramolecular ensemble of oligomers is used wherein the oligomers are products of the hydrolysis of biopolymers and the charge of the oligomer molecules is replaced with an opposite charge or in the case of the whole biopolymers is partially altered. By using this method it is possible to significantly reduce the costs of designing and synthesizing new drugs broaden the spectrum of action of existing genetically engineered protein drugs and create new classes of dynamic therapeutic and preventive drugs that self adapt to an organism and a target.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2010/000694 WO2012070968A1 (en) | 2010-11-22 | 2010-11-22 | Method for the molecular design and synthesis of therapeutic and preventive drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MN01218A true IN2013MN01218A (en) | 2015-06-12 |
Family
ID=46065142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1218MUN2013 IN2013MN01218A (en) | 2010-11-22 | 2010-11-22 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120130699A1 (en) |
| EP (1) | EP2644617A4 (en) |
| EA (1) | EA025399B1 (en) |
| IN (1) | IN2013MN01218A (en) |
| WO (1) | WO2012070968A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527142A1 (en) | 2011-05-24 | 2012-11-28 | Cryovac, Inc. | Multilayer polyester film for ready meals |
| US20140220556A1 (en) * | 2013-02-06 | 2014-08-07 | Artur Martynov | Method of Design and Synthesis of a New Drug |
| RU2646885C1 (en) * | 2017-02-15 | 2018-03-12 | Владимир Николаевич Коваль | Oligopeptide composition |
| US11191806B2 (en) * | 2018-05-04 | 2021-12-07 | Boris Farber | Polymyxin-based pharmaceutical composition for treating infectious diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5495423A (en) | 1993-10-25 | 1996-02-27 | Trustees Of Boston University | General strategy for vaccine and drug design |
| AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| US5854992A (en) | 1996-09-26 | 1998-12-29 | President And Fellows Of Harvard College | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| ATE359561T1 (en) | 1997-06-02 | 2007-05-15 | Univ Johns Hopkins | COMPUTER METHODS USING FREE ENERGY CALCULATION FOR LIGAND DESIGN AND PREDICTION OF BINDING TARGETS |
| US7396919B1 (en) * | 1998-07-17 | 2008-07-08 | Mirus Bio Corporation | Charge reversal of polyion complexes |
| US20030088366A1 (en) * | 2001-07-13 | 2003-05-08 | Neurocrine Biosciences, Inc. | Computational method for the design of screening libraries for superfamilies of molecular targets having therapeutic utility |
| US20040167090A1 (en) * | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| US7365058B2 (en) * | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
-
2010
- 2010-11-22 IN IN1218MUN2013 patent/IN2013MN01218A/en unknown
- 2010-11-22 EP EP10859902.8A patent/EP2644617A4/en not_active Withdrawn
- 2010-11-22 EA EA201300490A patent/EA025399B1/en not_active IP Right Cessation
- 2010-11-22 WO PCT/RU2010/000694 patent/WO2012070968A1/en not_active Ceased
-
2011
- 2011-02-01 US US12/931,469 patent/US20120130699A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120130699A1 (en) | 2012-05-24 |
| WO2012070968A1 (en) | 2012-05-31 |
| EP2644617A1 (en) | 2013-10-02 |
| EA201300490A1 (en) | 2014-03-31 |
| EP2644617A4 (en) | 2014-05-14 |
| EA025399B1 (en) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002094A1 (en) | Antibody molecules for cancer treatment. (divisional request 201803153) | |
| MX2024000208A (en) | Novel therapeutic delivery moieties and uses thereof. | |
| MX2009012650A (en) | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders. | |
| Braný et al. | Effect of cold atmospheric plasma on epigenetic changes, DNA damage, and possibilities for its use in synergistic cancer therapy | |
| JOP20210207B1 (en) | Targeted bonding compounds | |
| MX359953B (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein. | |
| MX2011008430A (en) | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER. | |
| BR112012029588A2 (en) | her3-related biological materials. | |
| EP4273782A3 (en) | A system, device and a method for providing a therapy or a cure for cancer and other pathological states | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| CO2022003552A2 (en) | Multispecific binding proteins for cancer treatment | |
| MX2014009909A (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen. | |
| IN2013MN01218A (en) | ||
| CY1119233T1 (en) | GENE PRODUCTS DIFFERENTLY DIFFERENT IN MEDICINES AND APPLICATIONS | |
| MX2017001898A (en) | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes. | |
| BR112012020373A8 (en) | isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent | |
| NO20054769D0 (en) | Substituted phenylalkanoic acids | |
| EA201491726A1 (en) | CONJUGATES OF BORONIC ACIDS OF OLIGONUCLEOTIC ANALOGS | |
| MX2009004243A (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use. | |
| BR112018006687A2 (en) | disease prevention, treatment and reversal using therapeutically effective amounts of active fatty acids | |
| DE602006020501D1 (en) | SYNTHETIC MECP2 SEQUENCE FOR PROTEIN SITE THERAPY | |
| RU2015128766A (en) | PARTICULAR VIRUS-ORIGINED PARTICLES AND THEIR APPLICATION | |
| PH12019502442A1 (en) | Variants of human bmp7 protein | |
| UY32830A (en) | PROCEDURES FOR THE STEREOSELECTIVE SYNTHESIS OF BICYCLIC HETEROCYCLES | |
| EA201300489A1 (en) | Modified anti-complex oligonucleotides with anti-cancer properties and method for their production |